Clinical Drug Investigation

• Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary Cardiovascular disease is a leading cause of death in Eastern Europe. Might lipid-modifying therapy help achieve total and LDL cholesterol goals in Hungarian patients with coronary risk factors?
  Clinical Drug Investigation™, September 01, 2007
• Absorption of Fentanyl from Fentanyl Buccal Tablet in Cancer Patients Cancer patients undergoing chemotherapy or radiotherapy may develop painful oral mucositis. How does the absorption profile of fentanyl buccal tablet compare in patients with and without mucositis?
  Clinical Drug Investigation™, September 01, 2007
• A Multicentre, Randomised, Double-Blind Study Comparing the Efficacy Low back pain relief with NSAIDs is an early management treatment option. How does intramuscular dexketoprofen compare with diclofenac therapy in terms of effectiveness, safety, and speed of action?
  Clinical Drug Investigation™, August 01, 2007
• Nicotine Patch for the Prevention of Postoperative Nausea and Vomiting Postoperative nausea and vomiting has been shown to be reduced significantly by smoking, but which of the approximately 4,000 substances in cigarette smoke acts as an antiemetic? Is it nicotine?
  Clinical Drug Investigation™, August 01, 2007
• Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children Appropriate antiretroviral therapy for HIV-infected children remains limited. Which nucleoside reverse transcriptase inhibitors are best for backbone treatment in combination antiretroviral therapy?
  Clinical Drug Investigation™, August 01, 2007
• Efficacy and Tolerability of Olmesartan Medoxomil in Patients Many patients with essential hypertension fail to achieve their goal BP with low-dose monotherapy. Might efficacy of olmesartan medoxomil improve by dose titration or addition of hydrochlorothiazide?
  Clinical Drug Investigation™, July 01, 2007
• Cost Effectiveness of Lopinavir/Ritonavir Compared with Atazanavir plus Rit If a new HIV drug combo can prevent or delay onset of later disease, major cost savings and quality-adjusted survival may result. How do these ARV therapies compare on cost-effectiveness and CHD risk?
  Clinical Drug Investigation™, July 01, 2007
• Cost-Efficacy Comparison among Three Antiretroviral Regimens in HIV-1 Specialty HIV drugs cost more and their increasing demand is a financial burden. If virological and immunological responses are considered along with cost, which of the 3 ARVs is most cost-effective?
  Clinical Drug Investigation™, July 01, 2007
• Double-Blind Comparison of Escitalopram and Duloxetine The tolerability profiles of antidepressants vary considerably across individual agents. How do escitalopram and duloxetine fare as effective and safe acute treatments for major depressive disorder?
  Clinical Drug Investigation™, July 01, 2007
• Imidapril and Candesartan Cilexetil in Patients with Hypertension Both ACE inhibitors and ARBs are effective treatments in hypertension. How do these two agents compare?
  Clinical Drug Investigation™, June 01, 2007
• Economic Burden of Haematological Adverse Effects in Cancer Patients Literature review indicating the need to understand the potential cost impact of haematological AEs to help evaluate the efficacy and safety of various cancer treatment options.
  Clinical Drug Investigation™, June 01, 2007
• Delapril plus Indapamide: A Review of the Combination Combining two or more antihypertensive agents from different drug classes is increasingly being recognised as the most effective means of achieving target BP values by pharmacological therapy means.
  Clinical Drug Investigation™, June 01, 2007
• Biphasic Insulin Aspart in Type 2 Diabetes Mellitus Intensive insulin regimens effectively manage complications but biphasic premixed insulin used once- or twice-daily may be preferred. Development of BIAsp 30 presents added benefits that are reviewed.
  Clinical Drug Investigation™, May 01, 2007
• Effectiveness and Safety of Ezetimibe Added to Statin Therapy Despite proven efficacy of statins, not all patients reach the treatment goal specified for their coronary risk group by the NCEP ATP III. Does adding ezetimibe pose significant benefit-to-risk ratio?
  Clinical Drug Investigation™, May 01, 2007
• Role of Lormetazepam in the Treatment of Insomnia in the Elderly Insomnia management in the elderly is challenging, especially because pharmacological therapy is controversial. However, sleep hygiene therapy may play a crucial role when combined with lormetazepam.
  Clinical Drug Investigation™, May 01, 2007
• Impact of Losartan on Stroke Risk in Hypertensive Patients in Primary Care A series of large-scale recent studies have shown that stroke is the most frequent cardiovascular complication of hypertension. Does Losartan lower that risk?
  Clinical Drug Investigation™, May 01, 2007
• Pantoprazole On-Demand Effectively Treats Symptoms in Patients with GERD How does pantoprazole compare with esomeprazole?
  Clinical Drug Investigation™, April 01, 2007
• Insulin Detemir Results in Less Weight Gain than NPH Insulin Insulin detemir may provide a clinical advantage in the treatment of overweight patients with type 2 diabetes.
  Clinical Drug Investigation™, April 01, 2007
• Oxycodone Hydrochloride Controlled-Release Tablet for Cancer Pain The first study of OCRT in a Chinese population offers interesting insights on dosing strategies.
  Clinical Drug Investigation™, April 01, 2007
• Prevention of Osteoporosis What is the long-term efficacy of ossein-hydroxyapatite compound (OHC) for preventing osteoporosis in women with osteopenia?
  Clinical Drug Investigation™, April 01, 2007